Dr. Anna K. Blakney is a bioengineer with training in drug delivery systems for the treatment and/or prevention of infectious diseases. Her background includes training in chemical and biological engineering, polymeric biomaterials, drug delivery, host response, immunology, vaccinology, molecular biology and formulation science. She is motivated to pursue translational designs that will impact populations in low-resource settings. Since December of 2016, she has been a Research Fellow in Prof. Robin Shattock‘s laboratory at Imperial College London, initially funded by a Whitaker Post-Doctoral Fellowship and subsequently by a Marie Curie Individual Research Fellowship, join with Prof. Molly Stevens. Her research focuses on optimization of molecular RNA design and formulation for enhanced protein expression and immune response in vivo.
In January 2021, she will being as an Assistant Professor in the Michael Smith Labs and School of Biomedical Engineering at the University of British Columbia.
Prior to joining Dr. Shattock’s group, Anna completed her PhD with Dr. Kim Woodrow in 2016 at the University of Washington in the Department of Bioengineering. Her research in the Woodrow lab focused on the development of an electrospun nanofiber platform for topical delivery of drug combinations, specifically antiretrovirals and contraceptives. Her graduate work was funded by NSF GRFP and an NIH Molecular Medicine Training Grant. Anna also received an NSF/USAID GROW Fellowship to spend 6 months studying how the BCG vaccine affects infant susceptibility to HIV in the laboratory of Dr. Heather Jaspan at the University of Cape Town. Anna received her B.S. in Chemical and Biological Engineering from University of Colorado at Boulder, in 2012. As an undergraduate in Dr. Stephanie Bryant‘s laboratory, she characterized the role of PEG-based hydrogel stiffness in the foreign body response and the anti-inflammatory properties of differentiating stem cells. She also completed an REU with Dr. William Wagner at the University of Pittsburgh that focused on using a biodegradable hydrogel for intramyocardial protein delivery.